Ergonex Pharma: Terguride receives FDA orphan drug designation for the treatment of pulmonary arterial hypertension
Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...
mehr